X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Gilead expand its liver portfolio with CymaBay’s investigational, MBX-8025 (seladelpar), an oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist for the treatment of primary biliary cholangitis (PBC) including pruritus.
Lead Product(s): Seladelpar
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MBX-8025
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $4,300.0 million Upfront Cash: $4,300.0 million
Deal Type: Acquisition March 22, 2024
Details:
MBX-8025 (seladelpar) is an investigational first-in-class oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist which is being evaluated for the treatment of Primary Biliary Cholangitis.
Lead Product(s): Seladelpar
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MBX-8025
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
Through the acquisition, Gilead expand its liver portfolio with CymaBay’s investigational, MBX-8025 (seladelpar), an oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist for the treatment of primary biliary cholangitis (PBC) including pruritus.
Lead Product(s): Seladelpar
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MBX-8025
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $4,300.0 million Upfront Cash: $4,300.0 million
Deal Type: Acquisition February 12, 2024
Details:
MBX-8025 (seladelpar) is an investigational first-in-class oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist which is being evaluated for the treatment of Primary Biliary Cholangitis.
Lead Product(s): Seladelpar
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MBX-8025
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
MBX-8025 (seladelpar) is an investigational treatment for people with PBC, is a first-in-class oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist which is being evaluated for the treatment of Primary Biliary Cholangitis.
Lead Product(s): Seladelpar
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MBX-8025
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Details:
MBX-8025 (seladelpar) is a first-in-class oral, selective peroxisome proliferator-activated receptor (PPAR) delta agonist, or delpar, shown to regulate critical metabolic and liver disease pathways in indications with high unmet medical need.
Lead Product(s): Seladelpar
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MBX-8025
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
MBX-8025 (seladelpar) is a first-in-class oral, selective peroxisome proliferator-activated receptor (PPAR) delta agonist, or delpar, shown to regulate critical metabolic and primary biliary cholangitis pathways in indications with high unmet medical need.
Lead Product(s): Seladelpar
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MBX-8025
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
CymaBay anticipates using the net proceeds to fund ongoing development of MBX-8025, including clinical trials targeting market expansion. Seladelpar is a first-in-class investigational, PPAR-δ agonist, for the treatment of people with primary biliary cholangitis.
Lead Product(s): Seladelpar
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MBX-8025
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $258.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 14, 2023
Details:
CymaBay anticipates using the net proceeds to fund ongoing development of MBX-8025, including clinical trials targeting market expansion. Seladelpar is a first-in-class investigational, PPAR-δ agonist, for the treatment of people with primary biliary cholangitis.
Lead Product(s): Seladelpar
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MBX-8025
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $225.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 11, 2023
Details:
MBX-8025 (seladelpar) is a first-in-class oral, selective peroxisome proliferator-activated receptor (PPAR) delta agonist, or delpar, shown to regulate critical metabolic and primary biliary cholangitis pathways in indications with high unmet medical need.
Lead Product(s): Seladelpar
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MBX-8025
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
